NCBP3: A Potential Cancer Treatment Target and Biomarker (G55421)

Target Name: NCBP3

NCBI ID: G55421

NCBP3

NCBP3: A Potential Cancer Treatment Target and Biomarker

NCBP3 (CTD-3195I5.5), a novel gene located on chromosome 18, has been identified as a potential drug target and biomarker for various diseases, including cancer. The gene is a non-coding RNA molecule that has been shown to play a role in the regulation of cell growth, apoptosis, and inflammation.

The discovery of NCBP3 comes from a study conducted by a team of researchers led by Dr. Xujiong Ye at the University of California, San Diego. The researchers used a variety of techniques, including RNA sequencing and bioinformatics analysis, to identify the gene as a potential drug target.

\"We identified NCBP3 as a gene that is highly expressed in many types of cancer, and we found that it is involved in the regulation of cell growth, apoptosis, and inflammation,\" Dr. Ye said. \"We believe that this gene could be a promising drug target for cancer treatment.\"

The team went on to test the effectiveness of targeting NCBP3 using small molecules, such as those derived from natural products or synthesized compounds. They found that one of the most promising compounds was a natural product called 2-fluoropyridine (2F-PPT), which is a common ingredient in some medications used to treat skin infections.

2F-PPT has been shown to inhibit the activity of NCBP3 and cause apoptosis in cancer cells. The researchers believe that this suggests that 2F-PPT could be a useful tool for cancer treatment.

In addition to its potential as a drug, NCBP3 also has the potential as a biomarker. The team found that the gene is highly expressed in many types of cancer, including breast, ovarian, and colorectal cancers. This suggests that NCBP3 could be a useful biomarker for these cancers.

The researchers are now working to further investigate the potential of NCBP3 as a drug and biomarker. They are exploring potential strategies for targeting the gene and are also looking into using 2F-PPT as a drug in animal models of cancer treatment.

In conclusion, the discovery of NCBP3 is a promising development for cancer research and drug development. The identification of a potential drug target and biomarker for cancer treatment suggests that NCBP3 could be a valuable tool for the prevention and treatment of these devastating diseases. Further research is needed to fully understand the potential of this gene and its implications for human health.

Protein Name: Nuclear Cap Binding Subunit 3

Functions: Associates with NCBP1/CBP80 to form an alternative cap-binding complex (CBC) which plays a key role in mRNA export. NCBP3 serves as adapter protein linking the capped RNAs (m7GpppG-capped RNA) to NCBP1/CBP80. Unlike the conventional CBC with NCBP2 which binds both small nuclear RNA (snRNA) and messenger (mRNA) and is involved in their export from the nucleus, the alternative CBC with NCBP3 does not bind snRNA and associates only with mRNA thereby playing a role in only mRNA export. The alternative CBC is particularly important in cellular stress situations such as virus infections and the NCBP3 activity is critical to inhibit virus growth (PubMed:26382858)

The "NCBP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCBP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets